适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Investigation of safety, tolerability and pharmacokinetics of multiple doses of NNC0113-6856 in healthy participants, including a subset of healthy Japanese participantsType 2 diabetesMedDRA version: 21.1Level: LLTClassification code: 10045242Term: Type II diabetes mellitus Class: 10027433CTIS2023-503891-26-00ovo Nordisk A/S170
进行中（未招募）
1 期
A study to learn more about how BAY3283142 moves into, through, and out of the body of healthy participants when taken together with atazanavir and to assess the proportion of BAY3283142 that reaches the blood when taken by mouth.MedDRA version: 20.1Level: LLTClassification code: 10054109Term: Non-proliferative diabetic retinopathy Class: 10015919MedDRA version: 23.1Level: PTClassification code: 10064848Term: Chronic kidney disease Class: 100000004857Chronic kidney diseaseCTIS2024-510856-11-00Bayer AG15
进行中（未招募）
1 期
A Randomized, Open-label, Single Dose, 3-Period, 6-Sequence Cross-Over Trial to Investigate the Relative Bioavailability of Apraglutide Versus the Reference Formulation Following Subcutaneous Administrations.CTIS2023-504430-22-00VectivBio AG33
进行中（未招募）
1 期
Phase I, double-blind, randomized, placebo-controlled study investigating the safety, tolerability and concentrations of the study product KAND145 in healthy volunteersMedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864Ovarian cancerCTIS2023-503909-11-00Kancera AB80
进行中（未招募）
1 期
A study to test how BI 764532 is taken up by tumours in people with small-cell lung cancer or neuroendocrine cancereuroendocrine carcinoma (NEC) or small cell carcinoma of any otherorigin, Small cell lung carcinoma (SCLC), Large cells neuroendocrine lung carcinoma (LCNEC)MedDRA version: 21.0Level: LLTClassification code: 10048683Term: Advanced cancer Class: 10029104CTIS2022-501818-54-00Boehringer Ingelheim International GmbH12